Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. Heart Valve Disease

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1445024

Global, Regional, and National Burden of Non-rheumatic Valvular Heart Disease and Its Projections to 2035: Comprehensive Analysis of the Global Burden of Disease Study 2019

Provisionally accepted
Tao  YingTao Ying1Qiong  NieQiong Nie1Wei  YanWei Yan1Han  WangHan Wang2*Jing  WuJing Wu1,3*
  • 1College of Medicine, Southwest Jiaotong University, Chengdu, China
  • 2Department of Cardiology, The Third People’s Hospital of Chengdu, Chengdu, China
  • 3Department of Geriatrics, The Third People’s Hospital of Chengdu, Chengdu, China

The final, formatted version of the article will be published soon.

Objective: Valvular heart disease has attracted global attention as the next heart epidemic. However, the control effect of non-rheumatic valvular heart disease (NRVHD) is not ideal. We systematically and comprehensively assessed the epidemiological information and attributable risk factors of NRVHD from 1990 to 2019, and projections by 2035. Methods: Data on NRVHD were from the Global Burden of Disease (GBD) 2019. We analyzed the disease burden by age, sex, and socio-demographic index (SDI) regions from 1990 to 2019 using the Joinpoint regression model. We calculated attributable mortality and disability-adjusted life years (DALYs) associated with potential risk factors using a comparative risk assessment. Additionally, Nordpred age-period-cohort analysis predicted the NRVHD burden for the next 15 years. Results: From 1990 to 2019, incident, prevalent, and death cases, and DALYs of NRVHD gradually increased globally. The age-standardized incidence (ASIR) and prevalence rate (ASPR) of NRVHD continued to increase, while age-standardized mortality (ASMR) and DALYs rate (ASDR) gradually decreased. Subgroup analysis stratified by age, sex, and SDI regions suggested: (1) The global burden of NRVHD in women is generally decreasing. (2) In people older than 55 years, ASPR and ASIR continued to increase with aging, but the decline of ASMR and ASDR was relatively flat. (3) Despite an overall decline in ASMR and ASDR, the disease burden of NRVHD was highest in high SDI regions. High systolic blood pressure was the most prominent risk factor for NRVHD, with much higher mortality and DALYs than the high-sodium diet and lead exposure. The Nordpred age-period-cohort analysis demonstrated that ASIR (20.28 per 100,000 population) is on an upward trend, and ASMR (2.06 per 100,000 population) and ASDR(33.74 per 100,000 population) are on a downward trend in the next 15 years. Conclusion: The global burden of NRVHD remains high, especially among older adults and men in high SDI areas. However, ASMR and ASDR have declined for nearly 10 years and will likely continue to do so for the next 15 years. This suggests that current medical interventions and hypertension control strategies have been effective in reducing the NRVHD burden.

Keywords: Global burden of disease, GBD 2019, Non-rheumatic valvular heart disease, Epidemiology, projections

Received: 01 Oct 2024; Accepted: 10 Jul 2025.

Copyright: © 2025 Ying, Nie, Yan, Wang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Han Wang, Department of Cardiology, The Third People’s Hospital of Chengdu, Chengdu, China
Jing Wu, College of Medicine, Southwest Jiaotong University, Chengdu, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.